Park National Corp OH grew its position in shares of Merck & Co., Inc. (NYSE:MRK) by 3.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 422,012 shares of the company’s stock after buying an additional 15,898 shares during the quarter. Merck & Co., Inc. accounts for approximately 1.5% of Park National Corp OH’s investment portfolio, making the stock its 19th biggest holding. Park National Corp OH’s holdings in Merck & Co., Inc. were worth $27,022,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of the business. Cacti Asset Management LLC increased its stake in shares of Merck & Co., Inc. by 5.1% during the 3rd quarter. Cacti Asset Management LLC now owns 738,840 shares of the company’s stock worth $47,308,000 after purchasing an additional 35,997 shares during the last quarter. Perpetual Ltd increased its stake in shares of Merck & Co., Inc. by 3.5% during the 2nd quarter. Perpetual Ltd now owns 195,627 shares of the company’s stock worth $12,538,000 after purchasing an additional 6,650 shares during the last quarter. Bogart Wealth LLC increased its stake in shares of Merck & Co., Inc. by 42.7% during the 2nd quarter. Bogart Wealth LLC now owns 23,389 shares of the company’s stock worth $1,499,000 after purchasing an additional 6,998 shares during the last quarter. Davidson Kempner Capital Management LP purchased a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $4,807,000. Finally, Perigon Wealth Management LLC increased its stake in shares of Merck & Co., Inc. by 1.2% during the 2nd quarter. Perigon Wealth Management LLC now owns 120,512 shares of the company’s stock worth $7,780,000 after purchasing an additional 1,406 shares during the last quarter. 73.84% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Thomas H. Glocer sold 5,000 shares of Merck & Co., Inc. stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.25% of the company’s stock.
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. Merck & Co., Inc. had a net margin of 11.60% and a return on equity of 27.08%. The company had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. During the same period in the previous year, the firm posted $1.07 EPS. The firm’s revenue was down 2.0% compared to the same quarter last year. equities research analysts anticipate that Merck & Co., Inc. will post 3.95 earnings per share for the current year.
Merck & Co., Inc. announced that its board has initiated a share repurchase program on Tuesday, November 28th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 8th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.48 per share. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.47. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date is Thursday, December 14th. Merck & Co., Inc.’s payout ratio is currently 114.97%.
Several equities research analysts have recently issued reports on MRK shares. Jefferies Group restated a “sell” rating and set a $52.00 price target on shares of Merck & Co., Inc. in a research note on Sunday, August 20th. Credit Suisse Group decreased their price target on shares of Merck & Co., Inc. from $75.00 to $74.00 and set an “outperform” rating for the company in a research note on Wednesday, August 30th. Cowen restated a “hold” rating and set a $70.00 price target on shares of Merck & Co., Inc. in a research note on Friday, September 1st. BMO Capital Markets reiterated a “buy” rating and issued a $72.00 price objective on shares of Merck & Co., Inc. in a research note on Friday, September 8th. Finally, Zacks Investment Research lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the stock. Merck & Co., Inc. currently has a consensus rating of “Hold” and an average target price of $66.29.
TRADEMARK VIOLATION NOTICE: “Merck & Co., Inc. (MRK) Holdings Boosted by Park National Corp OH” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/12/18/merck-co-inc-mrk-holdings-boosted-by-park-national-corp-oh.html.
Merck & Co., Inc. Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.